Adverse kidney effects of epidermal growth factor receptor inhibitors.
The epidermal growth factor receptor (EGFR) is implicated in various malignancies. The past decade has seen the development and widespread use of EGFR inhibitors for the successful treatment of such cancers. Available EGFR inhibitors include small molecule tyrosine-kinase inhibitors and monoclonal antibodies. Class-related renal adverse events result in dual toxicity including tubular/electrolyte disorders and glomerulopathies. Tubular injury is common and mainly due to monoclonal antibodies while glomerulopathy is rare and related to various anti-EGFR agents. The exact pathogenesis of anti-EGFR agents associated with kidney disorders remains to be elucidated.
Department of Nephrology, Monceau Park International Clinic, Paris, France.
Hassan
H
Izzedine
Department of Nephrology, Yale University School of Medicine, New Haven, CT, USA.
Mark A
MA
Perazella
D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*
D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors
EGFR; electrolyte; glomerulopathy; hypomagnesemia; onconephrology